Concepts (188)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cytomegalovirus Infections | 8 | 2022 | 35 | 4.170 |
Why?
|
| Kidney Transplantation | 10 | 2024 | 120 | 3.910 |
Why?
|
| Organ Transplantation | 4 | 2022 | 30 | 1.720 |
Why?
|
| Anti-Infective Agents | 2 | 2022 | 36 | 1.610 |
Why?
|
| Cytomegalovirus | 5 | 2022 | 15 | 1.580 |
Why?
|
| Graft Rejection | 7 | 2024 | 63 | 1.580 |
Why?
|
| Transplant Recipients | 7 | 2023 | 22 | 1.410 |
Why?
|
| HIV Infections | 6 | 2024 | 463 | 1.130 |
Why?
|
| Retrospective Studies | 16 | 2023 | 3290 | 1.080 |
Why?
|
| Opportunistic Infections | 2 | 2017 | 7 | 1.070 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2022 | 115 | 1.040 |
Why?
|
| Cell-Free Nucleic Acids | 2 | 2022 | 12 | 1.010 |
Why?
|
| Inpatients | 4 | 2023 | 132 | 0.990 |
Why?
|
| Patient Readmission | 3 | 2015 | 130 | 0.980 |
Why?
|
| Daptomycin | 1 | 2022 | 4 | 0.830 |
Why?
|
| Antimicrobial Stewardship | 1 | 2022 | 9 | 0.820 |
Why?
|
| Antiviral Agents | 3 | 2022 | 70 | 0.810 |
Why?
|
| Staphylococcal Infections | 2 | 2016 | 151 | 0.800 |
Why?
|
| Kidney Failure, Chronic | 3 | 2024 | 151 | 0.790 |
Why?
|
| Humans | 33 | 2024 | 25967 | 0.760 |
Why?
|
| Immunosuppressive Agents | 4 | 2016 | 122 | 0.760 |
Why?
|
| Cross Infection | 1 | 2023 | 277 | 0.730 |
Why?
|
| Adult | 15 | 2022 | 7351 | 0.730 |
Why?
|
| Hypoglycemia | 1 | 2020 | 12 | 0.720 |
Why?
|
| Hypoglycemic Agents | 1 | 2020 | 33 | 0.710 |
Why?
|
| Antifungal Agents | 2 | 2018 | 37 | 0.700 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 36 | 0.700 |
Why?
|
| Electronic Health Records | 1 | 2020 | 62 | 0.680 |
Why?
|
| Liver Transplantation | 2 | 2021 | 65 | 0.640 |
Why?
|
| Lung Transplantation | 2 | 2016 | 13 | 0.630 |
Why?
|
| United States | 8 | 2022 | 1972 | 0.630 |
Why?
|
| Anti-Bacterial Agents | 4 | 2023 | 338 | 0.630 |
Why?
|
| Cryptococcosis | 1 | 2018 | 5 | 0.600 |
Why?
|
| Population Health | 1 | 2018 | 4 | 0.600 |
Why?
|
| Consensus | 1 | 2018 | 83 | 0.590 |
Why?
|
| Risk Factors | 8 | 2022 | 2240 | 0.580 |
Why?
|
| Middle Aged | 14 | 2024 | 8508 | 0.570 |
Why?
|
| Ustilaginales | 1 | 2017 | 1 | 0.570 |
Why?
|
| Yeasts | 1 | 2017 | 3 | 0.570 |
Why?
|
| Dermatomycoses | 1 | 2017 | 2 | 0.570 |
Why?
|
| Fungemia | 1 | 2017 | 8 | 0.560 |
Why?
|
| Exanthema | 1 | 2017 | 12 | 0.560 |
Why?
|
| Staphylococcus lugdunensis | 1 | 2016 | 1 | 0.550 |
Why?
|
| Endocarditis, Bacterial | 1 | 2016 | 5 | 0.550 |
Why?
|
| Roseolovirus Infections | 1 | 2016 | 4 | 0.540 |
Why?
|
| Bacteremia | 1 | 2016 | 96 | 0.510 |
Why?
|
| Male | 17 | 2024 | 13984 | 0.510 |
Why?
|
| Liver Failure | 1 | 2015 | 8 | 0.490 |
Why?
|
| Renal Insufficiency | 1 | 2014 | 13 | 0.480 |
Why?
|
| Heart Transplantation | 1 | 2014 | 24 | 0.480 |
Why?
|
| International Classification of Diseases | 1 | 2014 | 12 | 0.470 |
Why?
|
| Aged | 9 | 2022 | 8704 | 0.440 |
Why?
|
| Pneumonia, Viral | 1 | 2015 | 85 | 0.440 |
Why?
|
| Tissue Donors | 5 | 2024 | 76 | 0.410 |
Why?
|
| Tissue and Organ Procurement | 2 | 2024 | 29 | 0.400 |
Why?
|
| Immunocompromised Host | 3 | 2017 | 43 | 0.400 |
Why?
|
| Time Factors | 5 | 2016 | 1361 | 0.390 |
Why?
|
| Young Adult | 6 | 2021 | 1848 | 0.380 |
Why?
|
| Lemierre Syndrome | 1 | 2011 | 1 | 0.380 |
Why?
|
| Postoperative Complications | 2 | 2024 | 862 | 0.380 |
Why?
|
| Graft Survival | 4 | 2024 | 92 | 0.370 |
Why?
|
| Proportional Hazards Models | 4 | 2016 | 326 | 0.370 |
Why?
|
| Incidence | 3 | 2021 | 706 | 0.360 |
Why?
|
| Female | 13 | 2024 | 14351 | 0.360 |
Why?
|
| Hospital Mortality | 3 | 2015 | 130 | 0.340 |
Why?
|
| Ganciclovir | 2 | 2022 | 8 | 0.340 |
Why?
|
| Multivariate Analysis | 3 | 2015 | 293 | 0.340 |
Why?
|
| Databases, Factual | 2 | 2021 | 324 | 0.280 |
Why?
|
| Directly Observed Therapy | 1 | 2006 | 2 | 0.280 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2006 | 60 | 0.270 |
Why?
|
| HIV Seropositivity | 1 | 2006 | 50 | 0.260 |
Why?
|
| Comorbidity | 3 | 2021 | 466 | 0.250 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 929 | 0.250 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 1710 | 0.230 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 145 | 0.230 |
Why?
|
| Kidney | 2 | 2023 | 155 | 0.220 |
Why?
|
| Hospitalization | 2 | 2021 | 290 | 0.210 |
Why?
|
| Cohort Studies | 3 | 2022 | 1815 | 0.210 |
Why?
|
| Linezolid | 1 | 2022 | 3 | 0.210 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2022 | 73 | 0.210 |
Why?
|
| Carbapenems | 1 | 2022 | 32 | 0.200 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2022 | 43 | 0.200 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2022 | 48 | 0.200 |
Why?
|
| Benchmarking | 1 | 2022 | 35 | 0.200 |
Why?
|
| Virus Diseases | 1 | 2022 | 9 | 0.200 |
Why?
|
| Vancomycin | 1 | 2022 | 51 | 0.200 |
Why?
|
| Pancreas Transplantation | 1 | 2021 | 16 | 0.190 |
Why?
|
| Medicare | 1 | 2022 | 114 | 0.190 |
Why?
|
| Pancreas | 1 | 2021 | 26 | 0.190 |
Why?
|
| Hepatitis C | 1 | 2021 | 43 | 0.190 |
Why?
|
| Rectal Prolapse | 1 | 2021 | 1 | 0.190 |
Why?
|
| Graft vs Host Disease | 1 | 2021 | 51 | 0.180 |
Why?
|
| Forecasting | 1 | 2021 | 91 | 0.180 |
Why?
|
| Adolescent | 2 | 2018 | 2062 | 0.180 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2021 | 21 | 0.180 |
Why?
|
| HIV-1 | 1 | 2022 | 223 | 0.180 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 62 | 0.180 |
Why?
|
| Insulin | 1 | 2020 | 76 | 0.170 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 4661 | 0.170 |
Why?
|
| Biomarkers | 1 | 2022 | 548 | 0.170 |
Why?
|
| Models, Biological | 1 | 2021 | 304 | 0.160 |
Why?
|
| Laparoscopy | 1 | 2021 | 159 | 0.160 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2018 | 2 | 0.150 |
Why?
|
| Urinary Tract Infections | 1 | 2017 | 29 | 0.140 |
Why?
|
| Saccharomyces | 1 | 2017 | 1 | 0.140 |
Why?
|
| Idarubicin | 1 | 2017 | 1 | 0.140 |
Why?
|
| Echinocandins | 1 | 2017 | 3 | 0.140 |
Why?
|
| Cryptococcus | 1 | 2017 | 2 | 0.140 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2017 | 6 | 0.140 |
Why?
|
| Amphotericin B | 1 | 2017 | 5 | 0.140 |
Why?
|
| Trichosporon | 1 | 2017 | 2 | 0.140 |
Why?
|
| Cytarabine | 1 | 2017 | 11 | 0.140 |
Why?
|
| Vidarabine | 1 | 2017 | 9 | 0.140 |
Why?
|
| Lipopeptides | 1 | 2017 | 10 | 0.140 |
Why?
|
| Voriconazole | 1 | 2017 | 11 | 0.140 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 8 | 0.140 |
Why?
|
| Salvage Therapy | 1 | 2017 | 36 | 0.140 |
Why?
|
| Fever | 1 | 2017 | 34 | 0.140 |
Why?
|
| Paecilomyces | 1 | 2016 | 2 | 0.140 |
Why?
|
| Herpesvirus 7, Human | 1 | 2016 | 2 | 0.140 |
Why?
|
| Herpesvirus 6, Human | 1 | 2016 | 3 | 0.140 |
Why?
|
| Lung Diseases, Fungal | 1 | 2016 | 10 | 0.140 |
Why?
|
| Biopsy | 1 | 2017 | 199 | 0.130 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2016 | 6 | 0.130 |
Why?
|
| Dyspnea | 1 | 2016 | 37 | 0.130 |
Why?
|
| Pharmacoepidemiology | 1 | 2016 | 4 | 0.130 |
Why?
|
| Medicare Part D | 1 | 2016 | 7 | 0.130 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 21 | 0.130 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 51 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 112 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 224 | 0.120 |
Why?
|
| California | 1 | 2014 | 27 | 0.120 |
Why?
|
| Florida | 1 | 2014 | 21 | 0.120 |
Why?
|
| Income | 1 | 2014 | 72 | 0.110 |
Why?
|
| Treatment Outcome | 3 | 2021 | 3292 | 0.110 |
Why?
|
| Prognosis | 1 | 2016 | 749 | 0.110 |
Why?
|
| Pilot Projects | 2 | 2021 | 375 | 0.110 |
Why?
|
| Residence Characteristics | 1 | 2014 | 208 | 0.100 |
Why?
|
| Age Factors | 1 | 2014 | 742 | 0.100 |
Why?
|
| Bacterial Typing Techniques | 1 | 2011 | 10 | 0.090 |
Why?
|
| Molecular Typing | 1 | 2011 | 8 | 0.090 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2011 | 9 | 0.090 |
Why?
|
| Genotype | 1 | 2011 | 335 | 0.090 |
Why?
|
| Cerebral Infarction | 1 | 2011 | 150 | 0.080 |
Why?
|
| Astacoidea | 1 | 2009 | 1 | 0.080 |
Why?
|
| Lung Diseases, Parasitic | 1 | 2009 | 1 | 0.080 |
Why?
|
| Paragonimiasis | 1 | 2009 | 1 | 0.080 |
Why?
|
| Paragonimus westermani | 1 | 2009 | 1 | 0.080 |
Why?
|
| Shellfish | 1 | 2009 | 2 | 0.080 |
Why?
|
| Pandemics | 2 | 2022 | 238 | 0.080 |
Why?
|
| Urban Health | 1 | 2006 | 21 | 0.070 |
Why?
|
| Attitude to Health | 1 | 2006 | 92 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2006 | 145 | 0.060 |
Why?
|
| Living Donors | 1 | 2023 | 7 | 0.060 |
Why?
|
| Waiting Lists | 1 | 2023 | 15 | 0.060 |
Why?
|
| Health Facilities | 1 | 2023 | 19 | 0.050 |
Why?
|
| Patients | 1 | 2023 | 31 | 0.050 |
Why?
|
| Proviruses | 1 | 2022 | 3 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 16 | 0.050 |
Why?
|
| Virus Latency | 1 | 2022 | 15 | 0.050 |
Why?
|
| Data Accuracy | 1 | 2022 | 3 | 0.050 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2022 | 2 | 0.050 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2021 | 15 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2021 | 129 | 0.050 |
Why?
|
| Hospitals | 1 | 2022 | 148 | 0.050 |
Why?
|
| Perineum | 1 | 2021 | 7 | 0.050 |
Why?
|
| Infection Control | 1 | 2022 | 163 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 104 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2021 | 139 | 0.040 |
Why?
|
| Microbiological Techniques | 1 | 2016 | 5 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2016 | 22 | 0.030 |
Why?
|
| Microscopy | 1 | 2016 | 10 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 2016 | 28 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2021 | 1646 | 0.030 |
Why?
|
| Recurrence | 1 | 2017 | 306 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 321 | 0.030 |
Why?
|
| Midwestern United States | 1 | 2016 | 62 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 197 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 713 | 0.030 |
Why?
|
| Food Parasitology | 1 | 2009 | 1 | 0.020 |
Why?
|
| Food Contamination | 1 | 2009 | 3 | 0.020 |
Why?
|
| Praziquantel | 1 | 2009 | 4 | 0.020 |
Why?
|
| Hemoptysis | 1 | 2009 | 7 | 0.020 |
Why?
|
| Anthelmintics | 1 | 2009 | 8 | 0.020 |
Why?
|
| Missouri | 1 | 2009 | 27 | 0.020 |
Why?
|
| Tuberculosis | 1 | 2009 | 19 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 342 | 0.020 |
Why?
|
| Animals | 1 | 2009 | 3386 | 0.010 |
Why?
|